75 results about "Wild Type Mouse" patented technology

The invention discloses a construction method for a conditional overexpression Yap1 gene mice model at an H11 locus. The construction method comprises the steps: firstly, obtaining an inducible Yap1 overexpression transgenic vector; then, obtaining transgenic F0-generation mice; next, enabling the F0-generation mice to mate with wild-type mice, carrying out passage and line establishment, and thusobtaining F1-generation mice; and carrying out expanding propagation of positive F1-generation mice, then mutually mating, and thus obtaining the conditional overexpression mice Yap1 animal model. The transgenic mice model constructed by the method can be used for studying the function of Yap1 in different tissues and different developmental stages and the action mechanism of Hippo signaling pathways, can also be used for studying the function of the Hippo signaling pathway in animal development, biotumorigenesis, regenerative medicine and other disciplines, and has important guiding significance on biological signal transduction studies.

The invention relates to the field of biotechnology, in particular to a method for constructing a lethal gene systemic knockout mouse model with a CRISPR/Cas9 system. The method includes the followingsteps that 1, an sgRNA sequence for efficiently identifying a lethal gene PAM region after knockout is designed; 2, mRNA or protein of Cas9 is mixed with the sgRNA designed in step 1, microinjectionis performed on any blastomere cell in a mouse two-cell embryo with the mixture, embryo transplantation is performed after injection, and strain gene identification is performed to obtain a chimeric positive founder with the lethal gene knocked out; 3, the positive founder and a wild-type mouse are mated to generate an F1 generation, a heterozygous F1-generation mouse with the lethal gene systemically knocked out is finally obtained after gene identification, and construction of the mouse model capable of realizing passage propagation is completed. Compared with the prior art in which a lethalgene systemic knockout mouse model is constructed by ES cell gene targeting, the method in the technical scheme has the advantages that the operation steps are simple, the operation difficulty is low, the production cycle is short, and the cycle is only about 4 months.

The invention discloses composition based on main components of Pu'er tea and the application thereof. The composition comprises tea brown pigment, tea polysaccharide, tea polyphenol, caffeine, gamma-aminobutyric acid and gallic acid. A wild type mouse embryo fibroblast is utilized to test the killing effect of DNA toxicity chemical substance to normal cells and the effect that the composition provided by the invention protects the normal cells from DNA damage and prevents apoptosis; the result shows that the composition provided by the invention can effectively prevent the normal cell death caused by DNA toxicity chemical substance; and further research shows that the composition provided by the invention does not protect tumor cell death caused by the DNA toxicity chemical compound, conversely, the composition provided by the invention can promote the killing effect of the DNA toxicity chemical compound to the tumor cells. Therefore, the composition can be used for protecting the normal cells during the chemotherapy of tumor patients and alleviating toxic side effects caused by tumor chemotherapy, and meanwhile sensibilizes chemotherapy drug, enhances chemotherapy effect, and improves survival quality of chemotherapy patients.

The invention relates to the technical field of medicine, and provides new application of macrophage beta-profilin-1, namely application of macrophage beta-profilin-1 to preparation of a drug for preventing or treating atherosclerosis. It is proved through experiments that in comparison with wild type mice, the serum total cholesterol content of macrophage beta-arrestin-1 specificity myelogenous knockout mice is remarkably increased, and it is found through oil red O dyeing that the aorta overall plaque area and the plaque area of aorta roots are obviously increased compared with those of the wild type mice. By changing the macrophage beta-arrestin-1 gene expression level through virus transfection, and it is found that macrophage phagocytosis lipid is increased by interfering beta-arrestin-1 expression and is decreased by overexpressing beta-arrestin-1. The results show that the beta-arrestin-1 gene has a protective effect on the severity degree and prognosis of atherosclerosis.

The invention provides a construction method of an SDK2 gene mutation mice model. The mice model comprises the following steps of designing and constructing sgRNA capable of specifically identifying an SDK2 gene on the basis of a CRISPR/Cas9 system, injecting the sgRNA and a targeting vector constructed on the basis of the sgRNA into a mice fertilized egg; and after embryo transplantation, screening out F0-generation mice with SDK2 gene mutation from the output mice, and hybridizing the F0-generation mice with wild type mice to obtain an F1-generation mice model with SDK2 gene mutation. The mice model constructed by the method can be stably passaged, the action mechanism of the SDK2 gene in mice hereditary cataract can be conveniently researched in practical application, and under the condition that human patient research materials are not easy to obtain and are restricted by medical ethics, the SDK2 gene can be stably cloned. The mice model provided by the invention can become an important tool in the research of hereditary cataract, and a research model capable of realizing stable heredity is provided in the research of pathogenesis, treatment methods, drug screening, cataract surgery and the like.

The invention relates to a method for constructing the regulation and expression of a protease, in particular to a method for constructing the regulation and expression of a hepatitis C virus NS3/NS4A protease; the genome of transgenic animals contains a transgene DNA of a coding hepatitis C virus NS3/NS4A, moreover a regulating gene sequence and a report gene sequence are added before a purpose gene HCV NS3/4A DNA so as to be capable of expressing the active NS3/NS4A protease on the condition of a regulating factor. The method for constructing the regulation and expression of the hepatitis Cvirus NS3/NS4A protease comprises the following contents: (1) constructing a eukaryotic expression vector which contains regulating sequences such as LoxP locus, Luciferase, and polyA and the like, is dually regulated by Tet and Cre/LoxP systems, and expresses the HCV NS3/4A protease; and (2) obtaining an NS3/4A mouse and a transgenic heterozygous mouse with the genetic background basically similar to the wild type mouse. The HCV NS3/NS4A transgenic mouse model obtained can be used for the hybridization with a double-transgenic mouse, and further obtains a three-transgenic mouse and is applied to the HCV pathogenesis research and drug screening as well as evaluation.

The invention discloses functions and application of responsive to centrifugal force and shear stress gene 1 (RECS1) to treatment of restenosis after vascular injury. An RECS1 knockout mouse and a wild type mouse are taken as experimental subjects, and detection on mouse internal membrane regeneration, vessel wall cell proliferation level and smooth muscle cell phenotype transformation is carried out by a vascular injury model. Detection results prove that by virtue of RECS1 knockout, internal membrane regeneration and cell proliferation can be obviously inhibited, and smooth muscle cells are inhibited to be transformed into synthetic phenotype from contractile phenotype. Therefore, the functions of the RECS1 to the restenosis after vascular injury are mainly embodied in that internal membrane regeneration, cell proliferation and smooth muscle cell phenotype transformation are promoted by the RECS1. Aiming at the functions of the RECS1, the RECS1 can be used as a drug target for screening medicines for preventing, relieving and/or treating the disease of restenosis after vascular injury; an inhibitor of the RECS1 can be used for preparing medicines and arterial stents for preventing, relieving and/or treating the restenosis after vascular injury.

Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin [alpha]5[beta]1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin [alpha]5[beta]1-mediated Rac1/PAK signaling to weaken cell-cell contacts. Subsequently, cANGPTL4 is associated with and declusters VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption. In vivo vascular permeability and metastatic assays performed using ANGPTL4-knockout and wild-type mice injected with either control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induced vascular leakiness and facilitated lung metastasis in mice. Therefore, our findings elucidate how cANGPTL4 induces endothelial disruption. Our findings have direct implications for targeting cANGPTL4 to treat cancer and other vascular pathologies.

The invention discloses functions and application of SHPS1 in treatment of post-vascular injury restenosis, belonging to the field of functions and applications of genes. SHPS1 gene knockout mice and wild type mice are taken as experimental subjects, and due to a vascular injury model, the mouse neointima formation, vascular wall cell proliferation level and smooth muscle cell phenotype transform are detected. The result proves that SHPS1 gene knockout can obviously promote neointima neogenesis and cell proliferation and promote transformation of smooth muscle cells from a shrinkage manner to a synthetic manner. Thus the functions of SHPS1 in post-vascular injury restenosis are realized, which mainly shows that SHPS1 has the functions of inhibiting neointima formation and cell proliferation and inhibiting smooth muscle cell phenotype transformation. Aiming at the functions of the SHPS1, the SHPS1 can be used for preparing medicines and arterial stents for preventing, relieving and/or treating the post-vascular injury restenosis.

The invention relates to new application of a dcf1 gene. A wild type mouse (serving as contrast) and a mouse with the dcf1 deleted are mainly adopted; western blotting is used for detecting reducing of myelin basic protein; immunohistochemistry and a transmission electron microscope are used for observing changing of the form of a myelin sheath; and then a behavioral experiment is used for showing that the mouse with the dcf1 deleted can simulate clinical symptoms of multiple sclerosis, then the mouse with the dcf1 deleted is subjected to rescue, and it is discovered that the dcf1 can cause myelin sheath remodeling and regeneration.

The invention discloses construction and application of a KRT10 site-directed gene knock-in P2A-CrePR1-T2A-tdTomato mouse model. A construction method comprises the following steps: preparing sgRNA, and constructing a Cas9/sgRNA plasmid; constructing a recombinant targeting vector in which a KRT10 fixed-site gene is knocked into P2A-CrePR1-T2A-tdTomato; injecting the Cas9/sgRNA plasmid and the recombinant targeting vector into a fertilized egg of a donor mouse to obtain a transfected fertilized egg; transplanting the transfected fertilized egg into a uterus of a pseudopregnant female mouse so as to birth F0-generation mice, carrying out genotype identification on the F0-generation mice, and taking mice with positive homologous recombination as chimeric mice; hybridizing the chimeric mice with wild type mice, carrying out genotype identification on the offspring, and taking mice with positive homologous recombination as F1-generation mice; and hybridizing the F1-generation mice, and identifying that descendant mice which are correctly recombined and are not randomly inserted are mouse models.

The invention discloses a CAMSAP1 protein and the application of a gene thereof as an epileptic drug target. The 13th exon of CAMSAP1 is selected as a target site, and a wild mouse is knocked out through a homologous recombination method to acquire a knocked-out mouse. Experiments prove that compared with wild type mice, the knocked-out mouse is small in size and light in weight, and the death rate is increased. The CAMSAP1 protein is knocked out to change the polarity of neurons. The knocked-down CAMSAP1 protein can influence the transformation of neurons from multipolar cells to bipolar cells, resulting in abnormal migration of neurons along radial glial cells (the migration of neurons is influenced), and abnormal layered arrangement of neurons in cerebral cortex. The knocked-out CAMSAP1protein can cause epilepsy. Therefore, the CAMSAP1 protein can maintain normal growth of neurons and prevent and/or treat epilepsy. The CAMSAP1 protein and the application, which are provided by theinvention, have an important application value.

The invention relates to a construction method of a congenital cataract disease animal model, which comprises the steps of firstly, designing a gRNA target site sequence for a second exon region of a mouse GJA8 gene, amplifying a homologous arm and a cKO region, and respectively connecting the homologous arm and the cKO region to a vector; injecting positive clones into blastula by electroporation ES cells of the constructed plasmids, transferring the blastula into a mouse body, and obtaining a first builder mouse after a birth mouse is mature; mating with a wild type mouse to obtain a heterozygote mouse F1 generation with gene mutation; finally, mating the F1 generation of heterozygote mice with the same genotype to obtain F2 generation of gene mutation homozygote mice. According to the construction method of the congenital cataract disease animal model provided by the invention, typical characteristics of congenital cataract, such as crystalline lens degeneration opacity and crystalline lens epithelial apoptosis, can be obtained, the animal model can be used for researching congenital cataract diseases and screening medicines for treating the congenital cataract diseases, and application prospect is promising.

The invention discloses application of PSMB8 and a PSMB8 inhibitor to preparation of medicine for treating fatty liver and related diseases. Primary hepatocytes of C57BL/6 wild type mice and PSMB8 knock-down C57BL/6 mice are separated; the functions of PSMB8 gene are studied by a palmitate and oleic acid stimulation induced liver cell lipid accumulation model. The result proves that when the PSMB8expression is lowered, the PA+OA stimulation induced primary hepatocyte lipid accumulation is obviously reduced, i.e., the PSMB8 gene can promote the development and progression of fatty liver and related diseases; in an HFHC (high fat and high cholesterol) induced WT mouse fatty liver disease model, PR-957 can obviously inhibit HFHC induced weight increase, white grease increase and liver lipidaccumulation; the development and progression of the fatty liver and related diseases are inhibited. Therefore the PSMB8 provides a target for developing medicine for preventing, relieving and/or treating the fatty liver and related diseases.

The invention discloses an application of USP10 in hepatic ischemia reperfusion injury. A USP10 gene knockout mouse and a C57BL/6 wild type mouse are selected as experimental subjects, mouse hepatic ischemia reperfusion injury models are constructed respectively, the function of USP10 in hepatic ischemia reperfusion injury is researched, the new function of the USP10 gene in hepatic ischemia reperfusion injury is found, and the application of the USP10 gene in hepatic ischemia reperfusion injury is developed. The over-expression of the USP10 can relieve the hepatic ischemia reperfusion injury by inhibiting inflammation and cell apoptosis, so that the USP10 can be applied to the preparation of the medicine for preventing/treating the hepatic ischemia reperfusion injury, and a new medicine target is provided for the hepatic ischemia reperfusion injury.

The invention relates to application of a gama-aminobutyric acid (GABA) translocator isoform I gene knockout mouse system in building a novel drug induced epilepsy animal model. According to the invention, a GAT1 gene knockout mouse is adopted to build an animal epilepsy model, the effect is compared with modeling by adopting wild type mice, and the method provided by the invention is proved to be with high success rate, high epilepsy level, stable state, difficulty in death and good repeatability, and can well meet the requirement of epileptic disease research. The result provided by the invention also proves that after GAT1 gene knockout, the mouse epilepsy susceptibility is increased, the GAT1 gene or protein can be used as a therapeutic target for epilepsy, and the level of the GAT1 gene or protein can be used as a biomarker for epilepsy diagnosis.

The present invention relates to applications of DCF1 gene knockout in preparation of drugs for alleviating Alzheimer's disease. According to the present invention, mainly wild type mice, dcf1 knockout mice and AD model mice are adopted as control, and Dcf1 gene knockout AD model mice are adopted as a research object; the thioflavine staining results of the mouse brain freezing slices show that the deposition of senile plaques can be reduced after DCF1 gene knockout; the observation results of the mouse spatial learning and memory ability from the ethology prove that the learning and memory ability of the mouse can be enhanced after DCF1 gene knockout; and the results show that the DCF1 gene knockout can alleviate Alzheimer's disease, and the gene target is provided for the development of the new AD treatment drug.